Giotrif 20 mg, 30 mg, 40 mg, 50 mg Film-coated tablets (tablets).
PDF Leaflet Revision Date: 8 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of locally advanced or metastatic NSCLC with EGFR mutations.
Dosage (summary)
40 mg once daily, can escalate to 50 mg if tolerated.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential fetal harm.
Key Drug Interactions
- P-glycoprotein inhibitors
- Strong P-glycoprotein inducers
Contraindications
- Hypersensitivity to afatinib
- Severe hepatic impairment
- Severe ocular conditions
Common side effects
- Diarrhoea
- Rash
- Stomatitis
- Nausea
- Vomiting
Counselling Points
- Take without food; avoid pregnancy; monitor for diarrhoea and skin reactions.
Serious warnings
- Interstitial Lung Disease
- Severe skin reactions
- Gastrointestinal perforations
Important Disclaimer
The Giotrif 20 mg, 30 mg, 40 mg, 50 mg Film-coated tablets (tablets). professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
